References
- 1. Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 2009; 101: 222-4.
- 2. GLOBOCAN 2008. Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. Available at: http://globocan.iarc.fr/
- 3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
- 4. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer. J Clin 2012; 62: 220-41.
- 5. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4; 876-90.
- 6. Krenzer S, Peterziel H, Mauch C, Blaber SI, Blaber M, Angel P, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol 2011; 131: 2281-8.
- 7. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007; 1776: 22-31.
- 8. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast ovarian and prostate cancers. Tumour Biol 2005; 26: 324-36.
- 9. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505-11.
- 10. Clements JA. Reflections on the tissue kallikrein and kallikrein-related peptidase family -from mice to men - what have we learnt in the last two decades? Biol Chem 2008; 389: 1447-54.
- 11. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
- 12. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs; ascancer biomarkers. Clin Chem 2008; 54: 1600-7.
- 13. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikreinrelated peptidases in human malignancies. Future Oncol 2010; 6: 269-5.
- 14. Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer the new frontier. Biol Chem 2010; 391: 299-310.
- 15. Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006; 387: 643-562.
- 16. Schmitt M Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 2009; 101: 222-4.
- 17. Yousef GM, Diamandis EP. The human kallikrein gene family: new biomarkers for ovarian cancer. Cancer Treat Res 2009; 149: 165-87.
- 18. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005; 97: 307-9.
- 19. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291-300.
- 20. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21(10 Suppl): 206s-10s.
- 21. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer international FIGO Stages IIA-IV: analysis of the OVCAD data. Int JGynecol Cancer 2012; 22: 380-5.
- 22. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. CochraneDatabase Syst Rev CD007565; 2011.
- 23. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-32.
- 24. Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, et al. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Biol Chem 2006; 387: 1121-8.
- 25. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, et al. Primary tumor levels of human tissue kallikreins impact surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007; 13: 1742-8.
- 26. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem 2006; 52: 1879-86.
- 27. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-7.
- 28. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, et al. A multiparametric panel for ovarian cancer diagnosis prognosis response to chemotherapy. Clin Cancer Res 2007; 13: 6984-92.
- 29. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90: 686-92.
- 30. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 2006; 103: 405-16.
- 31. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003; 9: 1710-20.
- 32. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, et al. Human kallikrein 4 (KLK4; is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001; 7: 2363-71.
- 33. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol 2005; 96: 684-94.
- 34. Shvartsman HS, Lue J, Lillie J, Deavers MT, Clifford S, Wolf JK, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. GynecolOncol 2003; 90: 44-50.
- 35. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O’Brien TJ. Increased expression of protease M in ovarian tumors. Tumour Biol 2001; 22: 11-8.
- 36. Tanimoto H, Underwood LJ, Shigemasa K, Yan MS, Clarke J, Parmley TH, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999; 86: 2074-82.
- 37. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Doré JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br JCancer 2009; 101: 1107-13.
- 38. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family KLK14 which is down-regulated in different malignancies. Cancer Res 2001; 61: 3425-31.
- 39. Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer Am J Clin Pathol 2003; 119: 346-55.
- 40. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgoño C, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003; 21: 3119-26.
- 41. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 2009; 19: 1015-21.
- 42. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003; 63: 9032-41.
- 43. Diamandis EP, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, Dorn J, et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol 2003; 24: 299-309.
- 44. Diamandis EP, Scorilas A, Fracchioli S, van Gramberen M, de Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21: 1035-43.
- 45. Dorn J, Magdolen V, Gkazepis A, Gerte T, Harlozinska A, Sedlaczek P, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival. Ann Oncol 2011; 22: 1783-90.
- 46. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, et al. EP. Human kallikrein 8 a novel biomarker for ovarian carcinoma. CancerRes 2003; 63: 2771-4.
- 47. Koh SC, Razvi K, Chan YH, Narasimhan K, Ilancheran A, Low JJ, et al. The Ovarian Cancer Research Consortium of SE Asia. The association with age human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet 2011; 284: 183-90.
- 48. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 2002; 86: 1790-6.
- 49. Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, Valik D, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer 2008; 99: 1103-13.
- 50. zur Hausen H. Papillomaviruses - to vaccination and beyond. Biochemistry (Mosc) 2008; 5: 498-503.
- 51. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 15: 1144-53.
- 52. Micke O, Bruns F, Schäfer U, Prott FJ, Willich N. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo)-radiotherapy. Anticancer Res 2005; 25A: 1663-6.
- 53. Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, et al. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/ SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004; 12: 1001-6.
- 54. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization. BiolChem 2006; 387: 653-63.
- 55. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, de las Casas LE, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 2004; 2: 283-8.
- 56. Santin AD, Cane’ S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, et al. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/neuropsin/ovasin) is highly overexpressed in cervical cancer. Am J Obstet Gynecol 2004; 1: 60-6.
- 57. Termini L, Maciag PC, Soares FA, Nonogaki S, Pereira SM, Alves VA, et al. Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia. Int J Cancer 2010; 2: 485-90.
- 58. Bovicelli A, D’Andrilli G, Giordano A, de Iaco P. Conservative treatment of early endometrial cancer. J Cell Physiology 2012; 228: 1154-8.
- 59. Stuckey A. Breast cancer: epidemiology and risk factors. Clin ObstetGynecol 2011; 54: 96-102.
- 60. Marić P, Ozretić P, Levanat S, Oresković S, Antunac K, Beketić-Oresković L. Tumor markers in breast cancer--evaluation of their clinical usefulness. CollAntropol 2011; 35: 241-7.
- 61. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006; 52: 345-51.
- 62. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
- 63. Naidoo S, Raidoo DM. Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein. Oncol Rep 2009; 22: 285-93.
- 64. Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in nonsmall cell lung cancer by suppressing tumor cell invasiveness. Cancer Res 2006; 66: 11763-70.
- 65. Tham SM, Ng KH, Pook SH, Esuvaranathan K, Mahendran R. Tumor and microen- vironment modification during progression of murine orthotopic bladder cancer. Clin Dev Immunol 2011; 2011: 865684.
- 66. Mangé A, Desmetz C, Berthes ML, Maudelonde T, Solassol J. Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells Biochem Biophys Res Commun 2008; 375: 107-12.
- 67. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994; 54: 6344-7.
- 68. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostatespecific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998; 4: 1489-97.
- 69. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization. BiolChem 2006; 387: 653-63.
- 70. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate breast and ovarian cancers: from pathobiology to clinical relevance. BiolChem 2012; 393: 301-17.
- 71. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP. Kallikrein gene downregulation in breast cancer. Br J Cancer 2004; 90: 167-72.
- 72. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224: 1-22.
- 73. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br JCancer 1999; 79: 888-94.
- 74. Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999; 85: 891-8.
- 75. Lee JY, Park AK, Lee KM, Park SK, Han S, Han W, et al. Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis 2009; 30: 1528-31.
- 76. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006; 13: 57-9.
- 77. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exone sequencing identifies recurrent SPOP FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9.
- 78. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
- 79. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
- 80. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
- 81. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
- 82. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011; 39: 1183-92.
- 83. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J ClinOncol 2000; 18: 1036-42.
- 84. Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Sci 2010; 101: 693-9.
- 85. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure function and association to disease. Endocr Rev 2001; 22: 184-204.
- 86. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure unction and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010; 31: 407-46.
- 87. Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol Cancer Res 2009; 7: 129-41.
- 88. Olkhov-Mitsel E, van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, et al. Quantitative DNA methylation analysis of genes coding for kallikreinrelated peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012; 7: 1037-45.
- 89. Pampalakis G, Diamandis EP, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem 2006; 387: 795-9.
- 90. Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikreinrelated peptidases: there is a whole new world out there. Biol Chem 2012; 393: 319-30.
- 91. White NM, Youssef YM, Fendler A, Stephan C, Jung K, Yousef GM. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 2012; 393: 379-89.
- 92. Viatori M. Testicular cancer. Semin Oncol Nurs 2012; 28: 180-9.
- 93. Okamoto K. Epigenetics: a way to understand the origin and biology of testicular germ cell tumors. Int J Urol 2012; 19: 504-11.
- 94. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol 2010; 7: 610-7.
- 95. Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Rev AnticancerTher 2011; 11: 1-4.
- 96. Emerson RE, Ulbright TM. Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology 2010; 42: 344-55.
- 97. Favilla V, Cimino S, Madonia M, Morgia G. New advances in clinical biomarkers in testis cancer. Front Biosci 2010; 2: 456-77.
- 98. Chieffi P. New prognostic markers and potential therapeutic targets in human testicular germ cell tumors. Curr Med Chem 2011; 18: 5033-40.
- 99. Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS 2003; 111: 225-32.
- 100. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP. Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002; 60: 714-8.
- 101. Luo LY, Rajpert-de Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001; 85: 220-4.
- 102. Chang A, Yousef GM, Jung K, Rajpert-de Meyts E, Diamandis EP. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4; splice variants: differential expression in the human testis and testicular cancer. Anticancer Res 2001; 21: 3147-52.
- 103. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family KLK14 which is down-regulated in different malignancies. Cancer Res 2001; 61: 3425-31.
- 104. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. MolCancer 2009; 8: 20.